An Observational Study of Subcutaneous Implantable Cardioverter Defibrillator in Patients with Hypertrophic Cardiomyopathy At High Risk of Sudden Cardiac Death
1 other identifier
observational
589
1 country
1
Brief Summary
- 1.To observe the failure rate of S-ICD screening in HCM patients at high risk of SCD.
- 2.To observe the incidence of IAS in HCM patients with S-ICD implantation and explore the related factors of IAS.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2024
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2024
CompletedFirst Submitted
Initial submission to the registry
September 18, 2024
CompletedFirst Posted
Study publicly available on registry
September 19, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2028
September 19, 2024
September 1, 2024
3 years
September 18, 2024
September 18, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
the failure rate of S-ICD screening
S-ICD screening failed
3 months
The inappropriate shock event
The incidence of inappropriate shock event
3 months
Eligibility Criteria
The study was a multicenter, prospective, observational study that prospectively included HCM patients assessed as meeting the ICD implantation indication at Fuwai Hospital and National Collaborative Hospitals from July 1, 2024 to June 30, 2027.
You may qualify if:
- HCM patients assessed as meeting the ICD implantation indication
You may not qualify if:
- Combined with bradycardia with pacing indications;
- Frequent monomorphic ventricular tachycardia require ATP therapy;
- With indications of CRT;
- Combined with other diseases, life expectancy is less than 1 year.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fuwai hospital
Beijing, China, 100037, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 18, 2024
First Posted
September 19, 2024
Study Start
August 1, 2024
Primary Completion (Estimated)
July 31, 2027
Study Completion (Estimated)
July 31, 2028
Last Updated
September 19, 2024
Record last verified: 2024-09